Vimarsana
Biggest News Aggregation in the World

Immune Complex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immune Complex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immune Complex Today - Breaking & Trending Today

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo - Vimarsana News

Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) - Vimarsana News

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...

Natural bioactive molecules can relieve cold and flu symptoms - Vimarsana News

Natural bioactive molecules can relieve cold and flu symptoms

Researchers at Applied Biological Laboratories Inc. discovered how natural bioactive molecules can effectively relieve cold and flu symptoms by protecting the mucosal barrier function and reducing inflammation during these infections.

New: Cutting-edge natural bioactive molecules - Vimarsana News

New: Cutting-edge natural bioactive molecules

Clinical trial confirms natural bioactive molecules can effectively relieve cold and flu symptoms by protecting the mucosal barrier function and reducing inflammation.